Presurgical 68Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial

To see clear is not enough; it is the action that counts

“…Our editorial comments on a recent multicenter prospective phase 3 study by Djaïleb and coworkers (protocol registered in ClinicalTrials.com, NCT03368547/02611882/02919111) ( 5 ). Indirectly the study elucidated the paradox.…”

“…The patients were followed median 32.4 (interquartile range, 23.3–42.9) months. Ninety-one patients (38%) developed prostate-specific antigen (PSA) relapse [PSAR; previously denoted biochemical recurrence (BCR), as in the Djaïleb publication] ( 5 ).…”

“…The study had an overall relatively high frequency of PSAR. It reflected the patient selection with intermediate- and high-risk PCa as the largest subgroup of patients (80 patients, 33%) in the preoperative setting who had prostate biopsy results with ISUP grade 5 ( 5 ). The authors state that miN1/miM1 was a significant predictor of PSAR on a univariate basis.…”

“…The authors state that miN1/miM1 was a significant predictor of PSAR on a univariate basis. Djaïleb et al concluded that preoperative PSMA PET was a strong predictive biological indicator that increased PSAR risk assessment ( 5 ).…”

“…Feinstein called the consequence of the stage migration for a Will-Rogers phenomenon ( 17 ). Nevertheless, the Djaïleb study showed that the ignoring of the metastatic sites of PCa detected with staging PSMA PET/CT dominated for the risk of PSAR ( 5 ).…”